Project Grant R01CA303022
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $713K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of The University of Pennsylvania a $703,071 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on April 10, 2026, with completion targeted for March 31, 2031. This research initiative, conducted at the University of Pennsylvania in Philadelphia, focuses on defining the determinants of long-term CAR-T (Chimeric Antigen Receptor T-cell) cell persistence in blood cancer patients. The...
- The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...
- Federal Grant Award Summary The University of Pennsylvania received a $668,864 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded June 15, 2026, with completion targeted for May 31, 2031. This research initiative develops biomarkers to predict patient response to chimeric antigen receptor (CAR) T cell therapy for glioblastoma (GBM) and identifies mechanisms of treatment resistance. The project utilizes...
- This Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports fundamental research to develop chimeric antigen receptor (CAR) natural killer (NK) cell therapy as an effective immunotherapy against solid tumors. Awarded to Massachusetts General Hospital on August 6, 2025, with a completion date of July 31, 2028, the research addresses a critical gap in cancer treatment by leveraging NK cells' broad anti-tumor activity and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded the University of Pennsylvania $109,076 in Project Grant funding (Award Date: January 15, 2026; Completion Date: July 31, 2029) to support research investigating genes that limit Chimeric Antigen Receptor T (CAR T) cell persistence in solid tumors. The funded research focuses on identifying and characterizing genetic mechanisms—specifically the ATXN7L3 and...
- Federal Grant Award Summary The National Cancer Institute awarded the University of North Carolina at Chapel Hill a $2.55 million Project Grant (CFDA 93.395 Cancer Treatment Research) effective March 5, 2026, through February 28, 2031, to develop biomaterial-enhanced Chimeric Antigen Receptor (CAR) T-cell and Natural Killer T (NKT) cell therapies for glioblastoma treatment. The research program delivers three integrated research projects utilizing translational biomaterial strategies to...
- Federal Project Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $737,082 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to develop bioinspired virus-like nanovaccines designed to enhance chimeric antigen receptor (CAR) T cell therapy efficacy against solid tumors with antigen heterogeneity. The award, effective May 13, 2026 through April 30, 2031, supports development of an autologous...
- Federal Project Grant Award Summary Lifengine Animal Health Laboratories Incorporated received a $400,000 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded August 4, 2025, with completion targeted for July 31, 2027. The grant funds Phase I research to develop C-MYB-overexpressed chimeric antigen receptor T-cell (CAR-T) therapies designed to resist functional exhaustion and provide sustained anti-tumor activity. The project...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a $399,829 Project Grant on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on chimeric antigen receptor (CAR) dendritic cell (DC) immunotherapy for solid tumors. The project, which runs through April 30, 2028, will deliver mechanistic characterization and optimization of a novel DC-based therapeutic platform called AB7H3-TLR4 CAR-DCs—engineered...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of Pennsylvania $618,063 under the Cancer Treatment Research program (CFDA 93.395) to develop FLASH-CAR-T radioimmunotherapy as an innovative treatment approach for pediatric brain tumors, including medulloblastoma and glioma. The five-year project, which commenced July 1, 2026 and concludes June 30, 2031, will deliver research and development services focused on combining FLASH (fast low-dose-rate...